The report highlights the Alfresa Group's performance in the fiscal year ended March 31, 2022, against the backdrop of the COVID-19 pandemic, NHI drug price revisions, and a government order to suspend bidding nominations from medical institutions. The report outlines the Group's aspirations for the future, including its commitment to becoming a ""Healthcare Consortium"" that provides products and services in every health-related field. The report also details the Group's ESG initiatives, including environmental protection, diversity, and compliance.
Issuing Company Alfresa Holdings Corporation
Report Type Integrated Report
Report Language EN
Report Filesize 4.57 MB
No. of Pages 48 pages
Reporting periodApril 1, 2021-March 31, 2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; Ministry of Economy, Trade and Industry's Guidanc...
Materiality Assessmenttrue